Active Ingredient: Nadroparin
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
7,600 - 17,100 [iU]
From 7,600 To 17,100 [iU] once every day
Nadroparin should be injected subcutaneously once daily for the duration of 10 days in a dosage appropriately adjusted for the patient’s body weight (see Table below).
| Weight in kg | Treatment of deep venous thrombosis ml subcutaneous injection once daily |
|---|---|
| <50 | 0.4 ml |
| 50 to 59 | 0.5 ml |
| 60 to 69 | 0.6 ml |
| 70 to 79 | 0.7 ml |
| 80 to 89 | 0.8 ml |
| ≥90 | 0.9 ml |
Because of the risk of heparin-induced thrombocytopenia, the platelet count must be monitored regularly during treatment with nadroparin.
Checking the platelet count is recommended prior to initiating treatment, during the first day of treatment and subsequently every 3 to 4 days, as well as at the end of treatment.
Occasionally, a mild transient thrombocytopenia (Type I) with platelet counts between 100,000/microliter and 150,000/microliter (caused by transient platelet activation) occurs at the beginning of treatment. Complications generally do not occur in these cases. Treatment may, therefore, be continued.
Antibody-mediated severe thrombocytopenia (Type II) with platelet counts clearly below 100,000/microliter or a rapid drop to less than 50% of the initial value is rarely observed. In non-sensitized patients, platelet count decrease primarily starts 6 to 21 days after the onset of treatment; in sensitized patients, platelet count decrease may start within hours. The severe form of thrombocytopenia may be associated with arterial and venous thrombosis/thromboembolism, disseminated intravascular coagulation, and possible skin necrosis at the injection site, petechiae, purpura and melena. In such cases, nadroparin must be discontinued immediately and a different antithrombotic treatment must be considered. The patient must be informed that he or she may no longer use heparin-containing medications in the future.
For subcutaneous administration of nadroparin, the lateral abdominal wall is the usual site of injection. As an alternative, nadroparin can be injected into the thigh.
The needle is inserted perpendicularly into a fold of skin formed between the thumb and index finger that should be gently but firmly held until injection has been completed. The injection site should not be rubbed.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.
